Compare Stocks

→ The Next Nvidia? (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABGI ABG Acquisition Corp. I	$10.19	$10.17	$9.73 ▼ $10.42	$196.97M	-0.02	84,652 shs	2,100 shs
ARYD ARYA Sciences Acquisition Corp IV	$11.31	$11.24	$10.40 ▼ $11.35	$85.28M	N/A	24,405 shs	58 shs
GROY Gold Royalty	$1.92 -0.5%	$0.00	$1.18 ▼ $2.37	$279.05M	1.19	619,121 shs	364,644 shs
RACB Research Alliance Corp. II	$10.11	$9.83	$9.66 ▼ $11.33	$193.92M	0.04	43,159 shs	5 shs
VVOS Vivos Therapeutics	$2.66	$4.42	$2.40 ▼ $48.79	$7.26M	7.94	196,203 shs	63,256 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABGI ABG Acquisition Corp. I	0.00%	0.00%	0.00%	0.00%	0.00%
ARYD ARYA Sciences Acquisition Corp IV	0.00%	+0.09%	+0.69%	+2.82%	+8.75%
GROY Gold Royalty	0.00%	0.00%	0.00%	+10.97%	-19.93%
RACB Research Alliance Corp. II	0.00%	0.00%	0.00%	0.00%	0.00%
VVOS Vivos Therapeutics	-1.48%	-0.75%	-40.49%	-60.94%	-71.99%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABGI ABG Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARYD ARYA Sciences Acquisition Corp IV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GROY Gold Royalty	1.0591 of 5 stars	3.3	4.0	0.0	0.0	0.0	0.0	0.6
RACB Research Alliance Corp. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABGI ABG Acquisition Corp. I	N/A	N/A	N/A	N/A
ARYD ARYA Sciences Acquisition Corp IV	N/A	N/A	N/A	N/A
GROY Gold Royalty	2.67	Moderate Buy	$3.28	71.45% Upside
RACB Research Alliance Corp. II	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABGI ABG Acquisition Corp. I	N/A	N/A	N/A	N/A	($0.30) per share	N/A
ARYD ARYA Sciences Acquisition Corp IV	N/A	N/A	N/A	N/A	($3.49) per share	N/A
GROY Gold Royalty	$3.05M	91.49	N/A	N/A	$3.59 per share	0.53
RACB Research Alliance Corp. II	N/A	N/A	N/A	N/A	($0.27) per share	N/A
VVOS Vivos Therapeutics	$13.80M	0.53	N/A	N/A	$0.22 per share	12.09

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABGI ABG Acquisition Corp. I	-$740K	N/A	0.00	∞	N/A	N/A	-0.21%	0.01%	N/A
ARYD ARYA Sciences Acquisition Corp IV	-$2.13M	N/A	0.00	∞	N/A	N/A	-9.83%	-5.41%	N/A
GROY Gold Royalty	-$26.76M	-$0.18	N/A	N/A	N/A	-877.82%	-0.75%	-0.58%	N/A
RACB Research Alliance Corp. II	-$460K	N/A	0.00	∞	N/A	N/A	-1.44%	0.04%	N/A
VVOS Vivos Therapeutics	-$13.58M	-$11.05	N/A	∞	N/A	-98.42%	-665.17%	-122.48%	6/13/2024 (Estimated)

Latest RACB, ARYD, GROY, ABGI, and VVOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	VVOS Vivos Therapeutics	N/A	-$3.05	-$3.05	-$3.05	N/A	$3.25 million
3/27/2024	Q4 2023	GROY Gold Royalty	-$0.02	$0.01	+$0.03	$0.15	N/A	$1.02 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABGI ABG Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A
ARYD ARYA Sciences Acquisition Corp IV	N/A	N/A	N/A	N/A	N/A
GROY Gold Royalty	$0.01	0.52%	N/A	N/A	N/A
RACB Research Alliance Corp. II	N/A	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABGI ABG Acquisition Corp. I	N/A	0.84	0.84
ARYD ARYA Sciences Acquisition Corp IV	N/A	0.01	0.01
GROY Gold Royalty	0.06	1.44	1.44
RACB Research Alliance Corp. II	N/A	7.31	7.31
VVOS Vivos Therapeutics	N/A	0.34	0.34

Ownership

Institutional Ownership

Company	Institutional Ownership
ABGI ABG Acquisition Corp. I	71.63%
ARYD ARYA Sciences Acquisition Corp IV	48.08%
GROY Gold Royalty	33.75%
RACB Research Alliance Corp. II	91.90%
VVOS Vivos Therapeutics	26.35%

Insider Ownership

Company	Insider Ownership
ABGI ABG Acquisition Corp. I	22.10%
ARYD ARYA Sciences Acquisition Corp IV	53.45%
GROY Gold Royalty	N/A
RACB Research Alliance Corp. II	22.08%
VVOS Vivos Therapeutics	9.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ABGI ABG Acquisition Corp. I	2	19.33 million	15.06 million	Not Optionable
ARYD ARYA Sciences Acquisition Corp IV	3	7.54 million	3.51 million	Not Optionable
GROY Gold Royalty	4	145.72 million	N/A	Not Optionable
RACB Research Alliance Corp. II	3	19.19 million	14.95 million	Not Optionable
VVOS Vivos Therapeutics	154	2.73 million	2.47 million	Optionable

RACB, ARYD, GROY, ABGI, and VVOS Headlines

Source	Headline
	TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis americanbankingnews.com - April 15 at 6:20 AM
	Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short Interest americanbankingnews.com - April 12 at 3:04 AM
	Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval proactiveinvestors.com - April 11 at 3:32 PM
	Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices finance.yahoo.com - April 9 at 6:42 PM
	Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices markets.businessinsider.com - April 9 at 1:41 PM
	What's Going On With Vivos Therapeutics Stock? msn.com - April 9 at 1:41 PM
	Medicare to reimburse for Vivos CARE sleep apnea devices msn.com - April 9 at 1:41 PM
	Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement proactiveinvestors.com - April 9 at 9:31 AM
	Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today? investorplace.com - April 9 at 8:53 AM
	Vivos Therapeutics files to sell 1.73M shares of common stock for holders msn.com - April 9 at 8:41 AM
	Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement finance.yahoo.com - April 9 at 8:41 AM
	Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement globenewswire.com - April 9 at 7:30 AM
	Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report precisionmedicineonline.com - April 2 at 5:52 PM
	Vivos Therapeutics highlights path to cash flow positivity after FDA clearance proactiveinvestors.com - April 1 at 9:07 AM
	Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations finance.yahoo.com - March 31 at 1:42 PM
	Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript seekingalpha.com - March 30 at 12:38 PM
	Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss marketwatch.com - March 29 at 1:13 AM
	Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update globenewswire.com - March 28 at 4:05 PM
	Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call globenewswire.com - March 28 at 7:30 AM
	Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report benzinga.com - February 22 at 12:09 PM
	Vivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades benzinga.com - February 22 at 7:09 AM
	Vivos Therapeutics secures $4 million through warrant exercise investing.com - February 18 at 12:39 AM
	Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds finance.yahoo.com - February 15 at 9:27 AM
	Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant proactiveinvestors.com - February 15 at 9:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ABG Acquisition Corp. I

NASDAQ:ABGI

ABG Acquisition Corp. I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ABG Acquisition Corp. I was incorporated in 2020 and is based in New York, New York.

ARYA Sciences Acquisition Corp IV

NASDAQ:ARYD

ARYA Sciences Acquisition Corp IV does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Gold Royalty

NYSEAMERICAN:GROY

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. It focuses on acquiring royalties, streams, and similar interests at varying stages of the mine life cycle to build a portfolio offering near, medium, and longer-term attractive returns for its investors. The company's portfolio consists of net smelter return royalties ranging from 0.5% to 2.0% on 17 gold properties. Gold Royalty Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.

Research Alliance Corp. II

NASDAQ:RACB

Research Alliance Corp. II intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry. The company was incorporated in 2020 and is based in Las Vegas, Nevada.

Vivos Therapeutics

NASDAQ:VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial